Epitomee Medical

Proud of Dr. Gil Cohen's impactful presentation on Epitomee Medical’s oral delivery platform at PODD 2024! It was a fantastic opportunity to share our vision for needle-free biologic delivery with industry leaders. Looking forward to the exciting collaborations and innovations ahead! #PODD2024 #EpitomeeMedical #drugdelivery

Great achievement!

Epitomee Medical to Present Groundbreaking Results at ObesityWeek® 2024 Conference in Texas! We are thrilled to announce that Epitomee Medical intends to present the pivotal results of the RESET study at the upcoming ObesityWeek® 2024, one of the most prestigious global conferences focused on obesity science and treatment. The event will take place in San Antonio, Texas, from November 3 to 6, 2024. Our oral presentation, titled "Randomized Double-Blind Placebo-Controlled Study of a Novel Oral Hydrogel Capsule for Weight Loss," will be presented by Professor Jamy Ard on November 6th at 9:15 AM (CT). Professor Ard, an esteemed leader in obesity research and President-Elect of The Obesity Society (TOS), led the RESET study as Principal Investigator. The Obesity Society (TOS) is a leading organization dedicated to obesity science, treatment, and prevention. With over 2,800 members worldwide, TOS brings together clinicians, researchers and educators who are committed to advancing the understanding and management of obesity. ObesityWeek® is TOS’s premier annual event, featuring cutting-edge research, clinical applications, and policy discussions aimed at improving obesity care and prevention. The Epitomee® Capsule offers a unique, drug-free alternative to current treatments, using a cutting-edge ingestible medical device designed to support weight management and demonstrating effective and safe weight loss. Key results from the study, which helped secure FDA clearance, demonstrate: Significant weight loss compared to placebo (P<0.0001) High retention rates with a favorable safety profile Positive impact on health markers and quality of life improvements This is a pivotal moment for Epitomee and the wider medical community. Our mission is to make weight management solutions more accessible, offering new hope for individuals with a BMI of 25-40 who seek easy-to-use, tolerable options for long-term success. Join us at ObesityWeek® 2024 to learn more about this exciting development and how we’re transforming the future of Overweight and obesity treatment. #ObesityWeek2024 #EpitomeeMedical #RESETStudy #HydrogelTechnology #WeightLoss #MedicalInnovation #ObesityTreatment #FDAApproved #TheObesitySociety #TOS

Epitomee Medical is presenting our Breakthrough Oral Delivery Platform in the PODD 2024 in Boston, MA (October 28-29, 2024)! Join us to learn more from Gil Cohen PhD, VP R&D, how our platform transforms oral delivery of biologics: • Enabling oral delivery of significant amounts of large molecules, including proteins & peptides. • Dramatically boosting bioavailability, offering game-changing needle free alternative to injections. • Precisely transporting drugs to the small intestine and across the GI wall, ensuring effective bioavailability. Take advantage of this opportunity to elevate your drug delivery strategies with cutting-edge expertise of Epitomee Medical. Also meet our CEO, Dr. Dan Hashimshony and our VP of Business Development, Safi Landskroner. To arrange a meeting with us: https://lnkd.in/diZx-vHF PODD: Partnership Opportunities in Drug Delivery Community News https://lnkd.in/dx7wXfeN #PODD2024 #BiologicsDelivery #HealthcareInnovation #DrugDelivery #EpitomeeMedical #OralBiologics #PODDConference #OralDelivery #Biologics

Epitomee Medical is presenting our Breakthrough Oral Delivery Platform in the PODD 2024 in Boston, MA (October 28-29, 2024)! Join us to learn more from Gil Cohen PhD, VP R&D, how our platform transforms oral delivery of biologics: • Enabling oral delivery of significant amounts of large molecules, including proteins & peptides. • Dramatically boosting bioavailability, offering game-changing needle free alternative to injections. • Precisely transporting drugs to the small intestine and across the GI wall, ensuring effective bioavailability. Take advantage of this opportunity to elevate your drug delivery strategies with cutting-edge expertise of Epitomee Medical. Also meet our CEO, Dr. Dan Hashimshony and our VP of Business Development, Safi Landskroner. To arrange a meeting with us: https://lnkd.in/diZx-vHF PODD: Partnership Opportunities in Drug Delivery Community News https://lnkd.in/dx7wXfeN #PODD2024 #BiologicsDelivery #HealthcareInnovation #DrugDelivery #EpitomeeMedical #OralBiologics #PODDConference #OralDelivery #Biologics

Weight Management Breakthrough: FDA Clears Epitomee Medical's's Drug-Free Capsule for Adults with BMI 25-40kg/m² Epitomee Medical's drug-free weight management capsule has received FDA clearance, marking a significant innovation in weight loss solutions. The capsule expands in the stomach to create a feeling of fullness, reducing food intake without chemical intervention. In the 24-week RESET trial involving 279 participants, 55.5% of those treated with the Epitomee Medical Capsule achieved at least a 5% reduction in body weight, surpassing clinical benchmarks. Epitomee Medical CEO Dr. Dan Hashimshony emphasized the capsule's potential to address the global obesity epidemic, offering a non-invasive option for individuals with a BMI between 25 and 40 kg/m². For more details please click the link! https://lnkd.in/dZzUn_mB #marketaccess #reimbursement #pricing #hta #heor #healtheconomics #medicaldevices #pharmaceutical 

Exciting News! Epitomee Medical Receives FDA Clearance for Our Weight Management Capsule! We are proud to announce that the FDA has officially cleared the Epitomee® Capsule, a cutting-edge ingestible device designed to support weight management in adults with a Body Mass Index (BMI) of 25–40 kg/m². This groundbreaking, drug-free solution offers a safe and effective prescription option for those seeking an alternative to injectable treatments, and works alongside diet and exercise. The FDA clearance follows the successful results of the RESET study, a prospective, randomized, double-blind, placebo-controlled trial, which demonstrated significantly better weight loss among the device group compared to the control group (P<0.0001).  The study also confirmed a favorable safety profile, making this capsule a promising solution for millions of individuals managing their weight. Epitomee® Capsule was well tolerated and there were no serious adverse device effects (SADEs) in the study. In addition, subjects treated with Epitomee® Capsule showed better improvement in quality of life in several items of the IWQOL-Lite-CT questionnaire. We are excited to continue advancing the field of weight management and look forward to bringing this innovative product to global markets! For more details, you can read the full press release here: https://lnkd.in/dEfwk3bK #WeightManagement #FDAClearance #ObesityTreatment #HealthcareInnovation #Epitomee

We're excited to announce the submission of our groundbreaking Weight Loss Capsule for FDA clearance! This is a significant step towards commercializing our innovative solution in the US. We look forward to bringing this advancement to healthcare professionals & consumers, signaling a new chapter in weight management. For more details, read the full release here: https://lnkd.in/d7GK7_Xr Link to our website: https://lnkd.in/dFkNVr8r Donna Ryan Shimon Eckhouse Dan Hashimshony #thenewwaytomanageweight #Epitomee #qualityoflife #WeightManagement #FDA

Update from Epitomee - Our research, published in Obesity Pillars, offers new insights into the role of the Epitomee® Capsule in weight management.   Led by Haim Shirin, this further analysis demonstrates significant improvements in weight reduction and cardiovascular risk factors, alongside enhancements in PROs such as improved early satiety, decreased snacking, and reduced meal size with the Epitomee® Capsule. Read the full study here: https://lnkd.in/dXWNHUgu   Donna Ryan Dan Hashimshony Shimon Eckhouse   #EpitomeeMedical #WeightManagement #thenewwaytomanageweight #ObesityPillars

Following our recent update about completing the RESET trial on Epitomee® weight loss capsule, please note that the abstract- Baseline Characteristics of Participants in RESET, presented by Dr. Jamy Ard at Obesity Week, was published in the The Obesity Society Journal. Baseline characteristics of RESET participants broadly represent individuals with overweight or obesity, seeking weight loss treatment and confirms that appropriate population was recruited, allowing adequate investigation of the safety & effectiveness of Epitomee® for weight-reduction. Read the abstract on our site: https://lnkd.in/d-5hqGw9   Special thanks to Jamy Ard and Donna Ryan for their contributions.   Dan Hashimshony Shimon Eckhouse   #WeightLossInnovation #ObesityWeek #RESETTrial #ObesityJournal #thenewwaytomanageweight